Skip to main content

Mounjaro Beats Ozempic for Weight Loss

Medically reviewed by Carmen Pope, BPharm. Last updated on July 8, 2024.

By Dennis Thompson HealthDay Reporter

MONDAY, July 8, 2024 -- Mounjaro outperforms Ozempic in helping people lose weight, a new study shows.

People taking tirzepatide (Mounjaro, Zepbound) dropped significantly more pounds than those taking semaglutide (Ozempic, Wegovy), researchers reported July 8 in the journal JAMA Internal Medicine.

“Individuals with overweight or obesity treated with tirzepatide were significantly more likely to achieve clinically meaningful weight loss and larger reductions in body weight compared with those treated with semaglutide,” concluded the research team led by Dr. Nicholas Stucky, vice president of research with Truveta Inc., a medical research collective.

For the study, researchers tracked more than 18,000 overweight and obese people who were prescribed either drug to help control their type 2 diabetes between May 2022 and September 2023.

Both drugs initially were developed as type 2 diabetes medications, but were later approved for use in weight loss.

Results show that both drugs are effective in promoting some weight loss. Nearly 82% of patients taking Mounjaro lost 5% or more of their body weight, compared to nearly 67% of those taking Ozempic, researchers found.

However, Mounjaro users were more likely to achieve greater weight gain. About 42% of Mounjaro patients lost 15% or more of their body weight, compared to about 18% of those taking Ozempic.

Overall, patients on Mounjaro were 76% more likely than those on Ozempic to lose 5% or more of their body weight; 2.5 times more likely to lose 10% or more of their body weight; and 3.2 times more likely to lose 15% or more of their body weight, results show.

Mounjaro patients also experienced larger reductions in body weight throughout their first year on the drug, researchers added.

After three months, Mounjaro patients had lost about 6% of their body weight compared to under 4% for Ozempic patients. The difference was 10% versus 6% at six months, and 15% to 8% at one year.

Both drugs work by mimicking the effects of the gut hormone GLP-1, which plays a role in maintaining stable blood sugar levels. This action also slows digestion and increases satiety.

However, Mounjaro also stimulates a second gut hormone called GIP, which might explain the boosted effects found in this study.

Sources

  • JAMA Internal Medicine, news release, July 8, 2024

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted July 2024

Read this next

Belly Fat Linked To Psoriasis

THURSDAY, May 29, 2025 — Belly flab appears to be a stronger warning sign for psoriasis than fat located elsewhere on the body, a new study says. Fat around the abdomen is...

Shedding Pounds in Middle Age Could Add Years to Your Life, Study Finds

WEDNESDAY, May 28, 2025 — Losing just 6.5% of body weight in midlife may lower later risk of disease and premature death, new research shows. Researchers found that people...

Preschool BMI Can Predict Childhood Obesity Risk

WEDNESDAY, May 28, 2025 — Preschoolers who don’t naturally lose weight are more likely to develop full-fledged childhood obesity by age 9, a new study says. Most kids...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.